Eli Lilly and Company (NYSE:LLY) Shares Down 0.6% – Time to Sell?

Eli Lilly and Company (NYSE:LLY)’s stock price was down 0.6% on Wednesday . The stock traded as low as $897.84 and last traded at $907.50. Approximately 386,405 shares traded hands during trading, a decline of 87% from the average daily volume of 2,985,519 shares. The stock had previously closed at $913.32.

Wall Street Analyst Weigh In

A number of research firms have recently commented on LLY. Jefferies Financial Group lifted their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Truist Financial boosted their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $1,025.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Finally, Berenberg Bank boosted their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $979.29.

Eli Lilly and Company Trading Up 0.2 %

The company has a market cap of $870.15 billion, a P/E ratio of 134.34, a PEG ratio of 2.79 and a beta of 0.42. The business has a 50 day moving average price of $916.37 and a 200-day moving average price of $855.42. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. Analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Institutional Trading of Eli Lilly and Company

Several institutional investors and hedge funds have recently modified their holdings of the stock. Lynx Investment Advisory bought a new stake in Eli Lilly and Company in the 2nd quarter valued at about $32,000. LGT Financial Advisors LLC bought a new stake in Eli Lilly and Company in the second quarter worth $36,000. Cedar Mountain Advisors LLC lifted its position in Eli Lilly and Company by 53.3% in the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock valued at $41,000 after purchasing an additional 16 shares during the last quarter. Morton Brown Family Wealth LLC grew its holdings in Eli Lilly and Company by 45.5% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after acquiring an additional 15 shares during the last quarter. Finally, Unique Wealth Strategies LLC bought a new stake in shares of Eli Lilly and Company in the second quarter worth about $45,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.